Viking Global Opportunities GP LLC's Net Worth

$1.79 Billion

Estimate Recalculated Mar 1, 2024 09:02PM EST

Who is Viking Global Opportunities GP LLC?

Viking Global Opportunities GP LLC has an estimated net worth of $1.79 Billion. This is based on reported shares across multiple companies, which include Amylyx Pharmaceuticals, Inc., Adaptive Biotechnologies Corp, Zentalis Pharmaceuticals, Inc., RayzeBio, Inc., Editas Medicine, Inc., Inhibrx, Inc., Arbutus Biopharma Corp, Myovant Sciences Ltd., Roivant Sciences Ltd., PROCEPT BioRobotics Corp, BridgeBio Pharma, Inc., 4D Molecular Therapeutics, Inc., Rallybio Corp, Ginkgo Bioworks Holdings, Inc., APi Group Corp, FIGS, Inc., Urovant Sciences Ltd., Axovant Gene Therapies Ltd., and Frazier Lifesciences Acquisition Corp.

SEC CIK

Viking Global Opportunities GP LLC's CIK is 0001629476

Past Insider Trading and Trends

2019 was Viking Global Opportunities GP LLC's most active year for acquiring shares with 36 total transactions. Viking Global Opportunities GP LLC's most active month to acquire stocks was the month of January. 2022 was Viking Global Opportunities GP LLC's most active year for disposing of shares, totalling 22 transactions. Viking Global Opportunities GP LLC's most active month to dispose stocks was the month of August. 2019 saw Viking Global Opportunities GP LLC paying a total of $116,172,272.92 for 72,849,851 shares, this is the most they've acquired in one year. In 2020 Viking Global Opportunities GP LLC cashed out on 10,750,813 shares for a total of $271,743,539.29, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Amylyx Pharmaceuticals, Inc. (AMLX) Snapshot price: $15.305

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-10.26%
-1.40M
$29.80
-$41,719,639.31
12.24M
Sep 8 - Sep 9
Form 4
7.17M
$19.00
$43,700,000.00
7.17M
Jan 11 - Nov 11
Form 3
0
0
No matching records found

Adaptive Biotechnologies Corp (ADPT) Snapshot price: $3.575

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-7.46%
-2.50M
$49.52
-$123,787,500.00
30.99M
Nov 11
Form 4
-12.79%
-4.91M
$24.98
-$122,706,039.29
33.49M
Jan 28
Form 4
+2,595.20%
36.98M
$20.00
38.41M
Jul 1
Form 3
0
0
No matching records found

Zentalis Pharmaceuticals, Inc. (ZNTL) Snapshot price: $11.35

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-11.25%
-500.00K
$50.50
-$25,250,000.00
3.94M
Dec 1
Form 4
+19.50%
725K
$18.00
$13,050,000.00
4.44M
Apr 7
Form 3
0
0
No matching records found

RayzeBio, Inc. (RYZB) Snapshot price: $62.125

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-6.64M
0
Feb 26
Form 4
6.64M
$18.00
6.64M
Sep 19
Form 3
0
0
No matching records found

Editas Medicine, Inc. (EDIT) Snapshot price: $7.1553

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4/A
5.46M
5.46M
Feb 8 - Feb 8
Form 4
5.46M
5.46M
Feb 8 - Feb 8
Form 3
0
0
No matching records found